Biomedical Engineering Reference
In-Depth Information
[54] Petersen H, Fechner PM, Martin AL, Kunath K, Stolnik S, Roberts CJ, et al.
Polyethylenimine-graft-poly(ethylene glycol) copolymers: Influence of copolymer
block structure on DNA complexation and biological activities as gene delivery system.
Bioconjugate Chem 2002;13:845-54.
[55] Mishra S, Webster P, Davis ME. PEGylation significantly affects cellular uptake
and intracellular trafficking of non-viral gene delivery particles. Eur J Cell Biol
2004;83:97-111.
[56] Shi L, Tang GP, Gao SJ, Ma YX, Liu BH, Li Y, et al. Repeated intrathecal administra-
tion of plasmid DNA complexed with polyethylene glycol-grafted polyethylenimine led
to prolonged transgene expression in the spinal cord. Gene Ther 2003;10:1179-88.
[57] Benns JM, Maheshwari A, Furgeson DY, Mahato RI, Kim SW. FOL-PEG-FOL-graft-
polyethylenimine-based gene delivery. J Drug Target 2001;9:123-39.
[58] Kim SH, Jeong JH, Cho KC, Kim SW, Park TG. Target-specific gene silencing by siRNA
plasmid DNA complexed with FOL-modified poly(ethylenimine). J Control Release
2005;104:223-32.
[59] Cho KC, Kim SH, Jeong JH, Park TG. FOL receptor-mediated gene delivery using FOL-
poly(ethylene glycol)-poly (L-lysine) conjugate. Macromol Biosci 2005;5:512-19.
[60] Chiu SJ, Ueno NT, Lee RJ. Tumor-targeted gene delivery via anti-HER2 antibody (trastu-
zumab, Herceptin) conjugated polyethylenimine. J Control Release 2004;97:357-69.
[61] Merdan T, Callahan J, Petersen H, Kunath K, Bakowsky U, Kopeckova P, et al. Pegylated
polyethylenimine-FabV antibody fragment conjugates for targeted gene delivery to human
ovarian carcinoma cells. Bioconjugate Chem 2003;14:989-96.
[62] Jeong JH, Lee M, Kim WJ, Yockman JW, Park TG, Kim YH, et al. Anti-GAD anti-
body targeted non-viral gene delivery to islet beta cells. J Control Release 2005;107:
562-70.
[63] Kircheis R, Wightman L, Schreiber A, Robitza B, Roessler V, Kursa M, et al.
Polyethylenimine/DNA complexes shielded by transferrin target gene expression to
tumors after systemic application. Gene Ther 2001;8:28-40.
[64] Kircheis R, Ostermann E, Kursa M, Wightman L, Wagner E. Tumor-targeted gene deliv-
ery: an attractive strategy to use highly active effector molecules in cancer treatment.
Gene Ther 2002;9:731-5.
[65] Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC. Detection of
tumor angiogenesis
in vivo
by alphaVbeta3-targeted magnetic resonance imaging. Nat
Med 1998;4:623-6.
[66] Erdreich-Epstein H, Shimada S, Groshen M, Liu LS, Metelitsa KS, Kim MF, et al.
Integrins alpha(v)beta3 and alpha(v)beta5 are expressed by endothelium of high-risk
neuroblastoma and their inhibition is associated with increased endogenous ceramide.
Cancer Res 2000;60:712-21.
[67] Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol
1996;12:697-715.
[68] Suh W, Han SO, Yu L, Kim SW. An angiogenic, endothelial-cell-targeted polymeric gene
carrier. Mol Ther 2002;6:664-72.
[69] Lynn DM, Anderson DG, Putnam D, Langer R. Accelerated discovery of synthetic trans-
fection vectors: parallel synthesis and screening of a degradable polymer library. J Am
Chem Soc 2001;123:8155-6.
[70] Lynn DM, Langer R. Degradable poly(beta-amino esters): synthesis, characterization,
and self-assembly with plasmid DNA. J Am Chem Soc 2000;122:10761-8.
[71] Danusso F, Ferruti P. Synthesis of tertiary amine polymers. Polymer 1970;11:88-113.
[72] Ferruti P, Barbucci R. Linear amino polymers-synthesis, protonation and complex-formation.
Adv Polym Sci 1984;58:55-92.
Search WWH ::
Custom Search